Immunic Therapeutics Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
95
- Stock Symbol
-
IMUX
- Investments
-
2
- Share Price
-
$7.57
- (As of Friday Closing)
Immunic Therapeutics General Information
Description
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Contact Information
Website
www.imux.comCorporate Office
- 1200 Avenue of the Americas
- Suite 200
- New York, NY 10036
- United States
Corporate Office
- 1200 Avenue of the Americas
- Suite 200
- New York, NY 10036
- United States
Immunic Therapeutics Timeline
Immunic Therapeutics Stock Performance
As of 13-Nov-2026, Immunic Therapeutics’s stock price is $7.57. Its current market cap is $119M with 15.9M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.57 | $7.79 | $5.06 - $17.43 | $119M | 15.9M | 336K | -$3.58 |
Immunic Therapeutics Financials Summary
As of 30-Sep-2026, Immunic Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (27,637) | 29,856 | 31,907 | 9,480 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (131,485) | (98,044) | (103,763) | (96,576) |
| Net Income | (128,296) | (97,172) | (100,507) | (93,612) |
| Total Assets | 136,423 | 24,052 | 40,868 | 54,299 |
| Total Debt | 646 | 577 | 1,004 | 1,334 |
Immunic Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Immunic Therapeutics Comparisons
Industry
Financing
Details
Immunic Therapeutics Competitors (8)
One of Immunic Therapeutics’s 8 competitors is Alaunos Therapeutics, a Formerly VC-backed company based in Fort Lauderdale, FL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alaunos Therapeutics | Formerly VC-backed | Fort Lauderdale, FL | ||||
| Carisma Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Poseida Therapeutics | Formerly VC-backed | San Diego, CA |
Immunic Therapeutics Patents
Immunic Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026093429-A1 | Triazolo compounds for treatment of bile acid diarrhea and autoimmune enteropathy | Pending | 31-Oct-2024 | ||
| WO-2026074007-A1 | Nurr1 agonists with replacement of the carboxylic acid or carboxamide moiety for use in the treatment of neurodegenerative diseases | Pending | 02-Oct-2024 | ||
| WO-2026017806-A1 | Triazolo compounds for use in the treatment of graft-versus-host disease | Pending | 18-Jul-2024 | ||
| WO-2025252661-A1 | Reducing body weight and/or induction of satiety by triazolo compounds | Pending | 03-Jun-2024 | ||
| AU-2025255879-A1 | Synthesis of vidofludimus and its calcium salt | Pending | 12-Apr-2024 |
Immunic Therapeutics Signals
Immunic Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Immunic Therapeutics Investments & Acquisitions (2)
Immunic Therapeutics’s most recent deal was a Merger/Acquisition with Vital Therapies. The deal was made on 12-Apr-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vital Therapies | 12-Apr-2019 | Merger/Acquisition | Biotechnology | ||
| 4SC (immunology portfolio) | 28-Sep-2016 | Corporate Asset Purchase | Buildings and Property |
Immunic Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.2 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Immunic Therapeutics FAQs
-
When was Immunic Therapeutics founded?
Immunic Therapeutics was founded in 2003.
-
Where is Immunic Therapeutics headquartered?
Immunic Therapeutics is headquartered in New York, NY.
-
What is the size of Immunic Therapeutics?
Immunic Therapeutics has 95 total employees.
-
What industry is Immunic Therapeutics in?
Immunic Therapeutics’s primary industry is Drug Discovery.
-
Is Immunic Therapeutics a private or public company?
Immunic Therapeutics is a Public company.
-
What is Immunic Therapeutics’s stock symbol?
The ticker symbol for Immunic Therapeutics is IMUX.
-
What is the current stock price of Immunic Therapeutics?
As of 13-Nov-2026 the stock price of Immunic Therapeutics is $7.57.
-
What is the current market cap of Immunic Therapeutics?
The current market capitalization of Immunic Therapeutics is $119M.
-
Who are Immunic Therapeutics’s competitors?
Alaunos Therapeutics, Carisma Therapeutics, Merck & Co., Adaptimmune Therapeutics, and Poseida Therapeutics are some of the 8 competitors of Immunic Therapeutics.
-
What is Immunic Therapeutics’s annual earnings per share (EPS)?
Immunic Therapeutics’s EPS for 12 months was -$3.58.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process